The targeted drug bevacizumab (Avastin) extends the amount of time women with advanced ovarian cancer live without their disease progressing, according to findings from two phase III clinical trials. The results were published December 29 in the New England Journal of Medicine.
In both trials, women initially received a combination of bevacizumab and standard chemotherapy, followed by bevacizumab alone for a defined period. Not enough time has passed in either trial to determine whether the approach extends lives (improves overall survival), although data from both trials suggest a possible small survival increase. Read more > >
A MESSAGE TO READERS
Miss a Story?
Since launching in 2004, we have published nearly 275 issues and over 3,800 cancer research news stories in the NCI Cancer Bulletin. All of these stories can be accessed through our archive/search page. You'll find some of the important research news and feature stories we covered last year on our 2011 Editors' Picks list.
If you are not yet a subscriber, please enter your e-mail address in the box in the top right-hand corner to begin your free subscription.
- Most States Fall Short of Requirements for Insurance Coverage of Cancer Clinical Trials
- Glycoscience, Disease, and Clinical Practice Symposium Will Be Held January 24
- Cyber-Seminar to Address the Delivery of Patient-Centered Cancer Care
- Genomics in Medicine Series Features Two Lectures on Cancer
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.